Wie hoch ist der Preis für Surrozen, Inc. (SRZN)

Preis für Surrozen, Inc. (SRZN) ist $21.57

Wie hoch ist die Marktkapitalisierung für Surrozen, Inc. (SRZN)

Marktkapitalisierung für Surrozen, Inc. (SRZN) ist $161.29M

Surrozen, Inc. (SRZN) KBV

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Jahr	P/B-Verhältnis	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

P/B-Verhältnis

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	P/B-Verhältnis	P/B-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Moderna, Inc. MRNA.US	3.7087	-	US
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH

Unternehmen

P/B-Verhältnis

P/B-Verhältnis-Differenz

Land